announced that on Wednesday its Compensation Committee approved the cancellation of previously granted stock options for key officers and directors, replacing them with restricted share units (RSUs) that vested immediately upon issuance. The decision comes as the biotech company, with a market capitalization of $42.4 million, has delivered a remarkable 185% return over the past year, though shares currently trade at $3.61.
According to a statement in the company’s SEC filing, the cancelled stock options and newly awarded RSUs were distributed as follows: Chief Executive Officer Geordan Pursglove had 350,000 options cancelled and received 350,000 RSUs; Chief Financial Officer Peter Stazzone had 50,000 options cancelled and received 50,000 RSUs; and directors Michael Holloway, Guy Primus, Lourdes Felix, and Jason Sawyer each had 25,000 options cancelled and received 25,000 RSUs.
The RSUs were granted under the company’s 2020 Stock Incentive Plan and each RSU entitles the recipient to one share of Lixte Biotechnology Holdings common stock upon vesting. The awards are subject to the terms and conditions of the plan and applicable award agreements.
The Compensation Committee determined that this change was intended to provide a more effective retention and incentive mechanism for the officers and directors involved. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with the company remaining unprofitable over the last twelve months. InvestingPro offers 5 additional exclusive tips for LIXT subscribers. The company’s filing noted that further details are available in the form of RSU Award Agreement and Stock Option Cancellation Agreement, which were included as exhibits to the 8-K report.
This information is based on a press release statement contained in the company’s SEC filing.
In other recent news, LIXTE Biotechnology Holdings has appointed Sidney Braun as the Chief Executive Officer of its subsidiary, Liora Technologies Europe Ltd. Braun has over 20 years of experience in the healthcare industry across multiple regions, including North America, Europe, and Israel. He played a key role in the creation of Liora and was pivotal in LIXTE’s acquisition of Liora’s assets from Orbit Capital, Inc. in November 2025. This leadership change is part of LIXTE’s ongoing strategy to strengthen its position in the biotechnology sector. The company has not released any recent earnings or revenue results. Analysts have not provided any recent upgrades or downgrades for LIXTE Biotechnology Holdings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.